Skip to main content
SpringerLink
Log in

Risk of anaemia, haemolysis with Soliris + Bexsero

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Health Canada. Summary Safety Review - SOLIRIS (eculizumab) and BEXSERO (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) - Assessing the Potential Risk of Hemolysis and Low Hemoglobin in Patients Treated with Soliris and Vaccinated with Bexsero. Internet Document : 16 Sep 2016. Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/soliris-bexsero-eng.php

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of anaemia, haemolysis with Soliris + Bexsero. Reactions Weekly 1621, 4 (2016). https://doi.org/10.1007/s40278-016-21557-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-016-21557-3

Search

Navigation